Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Conventional cancer therapies with chemodrugs suffer from various disadvantages, such as irreversible side effects on the skin, heart, liver, and nerves with even fatal consequences. RNA-based therapeutic is a novel technology which offers great potential as non-toxic, non-infectious, and well-tolerable platform. Herein, we introduce different RNA-based platforms with a special focus on siRNA, miRNA, and mRNA applications in cancer treatment in order to better understand the details of their therapeutic effects. Of note, the co-delivery of RNAs with other distinct RNA or drugs has provided safe, efficient, and novel treatment modalities for cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Applied biochemistry and biotechnology - 196(2024), 3 vom: 12. Feb., Seite 1685-1711 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tabasi, Hamed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer-therapy |
|---|
| Anmerkungen: |
Date Completed 20.02.2024 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12010-023-04597-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35903232X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35903232X | ||
| 003 | DE-627 | ||
| 005 | 20240220232142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12010-023-04597-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM35903232X | ||
| 035 | |a (NLM)37402038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tabasi, Hamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.02.2024 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Conventional cancer therapies with chemodrugs suffer from various disadvantages, such as irreversible side effects on the skin, heart, liver, and nerves with even fatal consequences. RNA-based therapeutic is a novel technology which offers great potential as non-toxic, non-infectious, and well-tolerable platform. Herein, we introduce different RNA-based platforms with a special focus on siRNA, miRNA, and mRNA applications in cancer treatment in order to better understand the details of their therapeutic effects. Of note, the co-delivery of RNAs with other distinct RNA or drugs has provided safe, efficient, and novel treatment modalities for cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer-therapy | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Oligonucleotide | |
| 650 | 4 | |a mRNA | |
| 650 | 4 | |a miRNA | |
| 650 | 4 | |a siRNA | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a RNA, Double-Stranded |2 NLM | |
| 700 | 1 | |a Mollazadeh, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Fazeli, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Abnus, Khalil |e verfasserin |4 aut | |
| 700 | 1 | |a Taghdisi, Seyed Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Ramezani, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Alibolandi, Mona |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied biochemistry and biotechnology |d 1981 |g 196(2024), 3 vom: 12. Feb., Seite 1685-1711 |w (DE-627)NLM012691364 |x 1559-0291 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2024 |g number:3 |g day:12 |g month:02 |g pages:1685-1711 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12010-023-04597-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2024 |e 3 |b 12 |c 02 |h 1685-1711 | ||